mRNA |
Erlotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.089 |
0.01 |
mRNA |
blebbistatin |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.01 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.088 |
0.01 |
mRNA |
FGIN-1-27 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.01 |
mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
BRD-K45681478 |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.01 |
mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.088 |
0.02 |
mRNA |
Repligen 136 |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.02 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.081 |
0.02 |
mRNA |
RDEA119 |
GDSC1000 |
pan-cancer |
AAC |
-0.072 |
0.02 |